openPR Logo
Press release

Burkholderia Infections Market: Applications and Global Markets

05-18-2017 12:40 AM CET | Health & Medicine

Press release from: Transparency Market Research

Burkholderia Infections Market: Applications and Global

Burkholderia cepacia is an aerobic gram-negative bacillus that can be found in soil and water. Burkholderia cepacia is an organism of low virulence and are often resistant to common antibiotics. Burkholderia cepacia is considered as a colonizing bacterium rather than infecting bacterium. Burkholderia cepacia is considered as less risky for healthy people, however, people with chronic lung diseases (asthma, CFTR and COPD) are at high risk for suffering from burkholderia cepacia infections.

View Report @ http://www.transparencymarketresearch.com/burkholderia-infections-market.html

Signs and symptoms of burkholderia cepacia infection can vary from person to person with no symptoms to serious respiratory medical conditions. Burkholderia cepacia infection can be transmitted through contaminated medical devices, person-to-person contact and contact with contaminated surfaces. Other possible complications caused due to burkholderia cepacia include soft-tissue infections, surgical-wound infections and genitourinary tract infections. Burkholderia cepacia may also cause catheter-related infections in patients with cancer.

Burkholderia Infections Market: Trends and Dynamics

The prevalence of chronic lung diseases (asthma, CFTR and COPD) is increasing at a rapid pace across the world. Exact cause for asthma and cystic fibrosis is unknown, but the risk factors include hereditary conditions (passed from generation to generation) and environmental pollution (UV ray, chemical irritant). On the other hand, COPD is mostly caused due to cigarette smoking. According to the Centers for Disease Control and Prevention (CDC), North America accounted for the highest number of asthma and COPD cases in the world in 2012.

Likewise, the American Academy of Allergy Asthma and Immunology estimated in 2012, that more than 100 million people would suffer from asthma across the world by 2025. According to the U.S Cystic Fibrosis Foundation, Europe accounted for the largest prevalence of cystic fibrosis cases in 2012. Moreover, prevalence of asthma is observed more in case of children and geriatric population compared to adults. According to an article published by the American Academy of Allergy, Asthma and Immunology, in 2012, nearly 10% children and 8% adults in the U.S. were diagnosed with asthma.

Get accurate market forecast and analysis on the Burkholderia Infections Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15479

Thus, growing pace of chronic lung diseases drives the global burkholderia cepacia infections treatment market. Moreover, technological advancement in diagnostic test further accentuates the global market demand of burkholderia cepacia infections treatment. There is no significant sign and symptom has been identified for infection with burkholderia cepacia. Thus, lack of awareness among people about burkholderia infections might restrict the global market demand of burkholderia cepacia infections treatment.

Burkholderia Infections Market: Region-wise Outlook

North America dominates the global market for burkholderia cepacia infections treatment due to strong demand of diagnostic test in this region. Moreover, increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global burkholderia cepacia infections treatment market due to the presence of large geriatric population base in European region. Asia-Pacific is considered as an untapped market due to lack of proper healthcare facilities in some Asian countries.

Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market due to growing market penetration in this region. Rest of the world (RoW) holds fourth position in the global burkholderia cepacia infections treatment market due to poor economic and health condition in most of the African countries.

Burkholderia Infections Market: Key Players

Various key players contributing the global market share of burkholderia cepacia infections treatment market include Novabiotics Ltd, Aridis Pharmaceuticals LLC, NanoBio Corporation, iQur Ltd. among others.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Burkholderia Infections Market: Applications and Global Markets here

News-ID: 540887 • Views:

More Releases from Transparency Market Research

Gas Compressor Market Outlook 2036: Global Industry Expected to Reach US$ 41.0 Billion by 2036 at 5.3% CAGR
Gas Compressor Market Outlook 2036: Global Industry Expected to Reach US$ 41.0 B …
The global gas compressor market was valued at US$ 23.2 Bn in 2025 and is projected to reach US$ 41.0 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2036. This steady growth trajectory reflects the structural importance of gas compression systems across upstream, midstream, and downstream gas value chains. Rising natural gas consumption, expansion of pipeline and LNG infrastructure, and national energy
Anesthesia Drugs Market to be Worth USD 12.6 Bn by 2036 - By Drug / By Application | U.S. • Germany • China • India
Anesthesia Drugs Market to be Worth USD 12.6 Bn by 2036 - By Drug / By Applicati …
The global anesthesia drugs market was valued at US$ 7.6 billion in 2025 and is projected to reach US$ 12.6 billion by 2036, expanding at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2036. This steady growth trajectory reflects the essential and non-substitutable role of anesthesia drugs in modern healthcare systems. As surgical interventions continue to rise globally-across both elective and emergency procedures-the demand for safe, effective,
Single-Atom Catalysts Market Size is Expected to Expand from US$ 177.8 Million to US$ 1,000.2 Million by 2036 at a 17.0% CAGR
Single-Atom Catalysts Market Size is Expected to Expand from US$ 177.8 Million t …
The global single-atom catalysts (SACs) market is poised for remarkable growth as industries seek highly efficient, cost-effective, and sustainable catalytic solutions. Valued at US$ 177.8 million in 2025, the market is projected to reach US$ 1,000.2 million by 2036, expanding at a robust compound annual growth rate (CAGR) of 17.0% from 2026 to 2036. This rapid expansion reflects the growing importance of advanced catalysis in energy, chemicals, environmental protection, and
Non-specific Endonuclease Market to Reach USD 726.6 Million by 2036, Supported by Biopharma Growth
Non-specific Endonuclease Market to Reach USD 726.6 Million by 2036, Supported b …
The non-specific endonuclease market is witnessing steady growth, driven by the expanding use of molecular biology tools across biotechnology, pharmaceuticals, diagnostics, and academic research. Non-specific endonucleases are enzymes that cleave nucleic acids without requiring a specific recognition sequence, making them highly valuable for applications such as DNA/RNA degradation, sample preparation, viscosity reduction, and contamination control. Their broad activity profile differentiates them from restriction enzymes and enables versatile usage across multiple

All 5 Releases


More Releases for Burkholderia

Burkholderia Infections Market Trends, Regulations And Competitive Landscape Out …
Burkholderia cepacia is an aerobic gram-negative bacillus that can be found in soil and water. Burkholderia cepacia is an organism of low virulence and are often resistant to common antibiotics. Burkholderia cepacia is considered as a colonizing bacterium rather than infecting bacterium. Burkholderia cepacia is considered as less risky for healthy people, however, people with chronic lung diseases (asthma, CFTR and COPD) are at high risk for suffering from burkholderia
Burkholderia Infections Market
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,
Burkholderia Infections Market
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,
Burkholderia Infections Market - Global Industry Insights 2024
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,
Burkholderia Infections Market - Global Industry Insights 2024
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,
Recent research explores the Burkholderia Infections - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections Pipeline Review, H2 2016, provides an overview of the Burkholderia Infections (Infectious Disease) pipeline landscape. Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics. Click here to know more about